CEA cell adhesion molecule pseudogene 8Genealiases: CEACAM29P · CGM15
Q-omics provides the consensus-scored CEACAMP8 profile across patient tissues and cancer cell-line models. CEACAMP8 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CEACAMP8 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, CEACAMP8 RNA expression shows 5,152 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, THCA, and STAD as cancer lineages where CEACAMP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEACAMP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEACAMP8 survival associations across molecular data types. CEACAMP8 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEACAMP8 RNA expression–survival associations across cancer types. High CEACAMP8 expression shows unfavorable associations in UCEC, TGCT, KICH, KIRC, PRAD and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CEACAMP8 RNA expression.
This table summarizes CEACAMP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CEACAMP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEACAMP8 shows higher tumor expression in THCA, LUAD and HNSC. The THCA box plot shows higher CEACAMP8 RNA expression in tumor versus normal tissue (log2 FC = +0.033, t-test p = .010).
This table shows molecular features associated with CEACAMP8 in patient tissues and cancer cell lines. In patient samples, CEACAMP8 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
